Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May;271(5):2503-2508.
doi: 10.1007/s00415-023-12174-3. Epub 2024 Jan 23.

Utility of genetic testing in the pre-surgical evaluation of children with drug-resistant epilepsy

Sarah Alsubhi  1 , Saoussen Berrahmoune  2 , Roy W R Dudley  2   3 , David Dufresne  4 , Elisabeth Simard Tremblay  1   5 , Myriam Srour  1   2   5 , Kenneth A Myers  6   7   8
Affiliations

Utility of genetic testing in the pre-surgical evaluation of children with drug-resistant epilepsy

Sarah Alsubhi et al. J Neurol. 2024 May.

Abstract

We evaluated the utility of genetic testing in the pre-surgical evaluation of pediatric patients with drug-resistant focal epilepsy. This single-center retrospective study reviewed the charts of all pediatric patients referred for epilepsy surgery evaluation over a 5-year period. We extracted and analyzed results of genetic testing as well as clinical, EEG, and neuroimaging data. Of 125 patients referred for epilepsy surgical evaluation, 86 (69%) had some form of genetic testing. Of these, 18 (21%) had a pathogenic or likely pathogenic variant identified. Genes affected included NPRL3 (3 patients, all related), TSC2 (3 patients), KCNH1, CHRNA4, SPTAN1, DEPDC5, SCN2A, ARX, SCN1A, DLG4, and ST5. One patient had ring chromosome 20, one a 7.17p12 duplication, and one a 15q13 deletion. In six patients, suspected epileptogenic lesions were identified on brain MRI that were thought to be unrelated to the genetic finding. A specific medical therapy choice was allowed due to genetic diagnosis in three patients who did not undergo surgery. Obtaining a molecular diagnosis may dramatically alter management in pediatric patients with drug-resistant focal epilepsy. Genetic testing should be incorporated as part of standard investigations in the pre-surgical work-up of pediatric patients with drug-resistant focal epilepsy.

Keywords: CHRNA4; Drug-resistant epilepsy; Epilepsy surgery; Genetic testing; NPRL3; SCN2A.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

References

    1. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshe SL, Perucca E, Wiebe S, French J (2010) Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51:1069–1077. https://doi.org/10.1111/j.1528-1167.2009.02397.x - DOI - PubMed
    1. Yoganathan K, Malek N, Torzillo E, Paranathala M, Greene J (2023) Neurological update: structural and functional imaging in epilepsy surgery. J Neurol 270:2798–2808. https://doi.org/10.1007/s00415-023-11619-z - DOI - PubMed - PMC
    1. Schur S, Moreau JT, Khoo HM, Koupparis A, Simard Tremblay E, Myers KA, Osterman B, Rosenblatt B, Farmer JP, Saint-Martin C, Turpin S, Hall J, Olivier A, Bernasconi A, Bernasconi N, Baillet S, Dubeau F, Gotman J, Dudley RWR (2022) New interinstitutional, multimodal presurgical evaluation protocol associated with improved seizure freedom for poorly defined cases of focal epilepsy in children. J Neurosurg Pediatr 29:74–82. https://doi.org/10.3171/2021.6.PEDS218 - DOI - PubMed
    1. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, Committee ALQA (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405–424. https://doi.org/10.1038/gim.2015.30 - DOI - PubMed - PMC
    1. Wolff M, Johannesen KM, Hedrich UBS, Masnada S, Rubboli G, Gardella E, Lesca G, Ville D, Milh M, Villard L, Afenjar A, Chantot-Bastaraud S, Mignot C, Lardennois C, Nava C, Schwarz N, Gerard M, Perrin L, Doummar D, Auvin S, Miranda MJ, Hempel M, Brilstra E, Knoers N, Verbeek N, van Kempen M, Braun KP, Mancini G, Biskup S, Hortnagel K, Docker M, Bast T, Loddenkemper T, Wong-Kisiel L, Baumeister FM, Fazeli W, Striano P, Dilena R, Fontana E, Zara F, Kurlemann G, Klepper J, Thoene JG, Arndt DH, Deconinck N, Schmitt-Mechelke T, Maier O, Muhle H, Wical B, Finetti C, Bruckner R, Pietz J, Golla G, Jillella D, Linnet KM, Charles P, Moog U, Oiglane-Shlik E, Mantovani JF, Park K, Deprez M, Lederer D, Mary S, Scalais E, Selim L, Van Coster R, Lagae L, Nikanorova M, Hjalgrim H, Korenke GC, Trivisano M, Specchio N, Ceulemans B, Dorn T, Helbig KL, Hardies K, Stamberger H, de Jonghe P, Weckhuysen S, Lemke JR, Krageloh-Mann I, Helbig I, Kluger G, Lerche H, Moller RS (2017) Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. Brain 140:1316–1336. https://doi.org/10.1093/brain/awx054 - DOI - PubMed

LinkOut - more resources